BioSpace News Archive

Global Transcatheter Heart Valves Market - New Product Launches to Drive Growth | Technavio

The latest market research report by Technavio on the global transcatheter heart valves market predicts a CAGR of around 16% during the period 2018-2022.

March 23, 2018
·
5 min read
Business

Philips provides University of Ottawa Heart Institute with innovative health technology solutions for their expanded cardiovascular care facility

Philips delivers patient monitoring, cardiac ultrasound and image guided therapy solutions to Canada’s largest heart health centre.; Solutions-based approach to support the hospital in working to better understand, treat and prevent heart disease.

March 23, 2018
·
4 min read
Teva Announces the Launch of a Generic Version of ALOXI® in the United States

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the launch of a generic version of ALOXI®1 (palonosetron HCI) injection, 0.25 mg/5 mL, in the United States

March 23, 2018
·
8 min read
Business

CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody

Crown Bioscience and a global drug discovery and development services company announced a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company.

March 23, 2018
·
3 min read
FDA

Canon Medical Systems’ Premium Ultrasound Provides New and Unique Features for a Wide Range of Liver Analysis

Industry’s Most Comprehensive Liver Analysis Suite with Attenuation Imaging and Shear Wave Dispersion

March 23, 2018
·
3 min read
Pharm Country

Anticancer Agent LENVIMA® Approved for Additional Indication of Unresectable Hepatocellular Carcinoma in Japan, First Approval Worldwide for LENVIMA for HCC

First New Front-Line Treatment Option for HCC Approved in Japan in Nearly 10 Years

March 23, 2018
·
40 min read
Drug Development

Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX® (varenicline) in Adolescent Smokers

The study is a regulatory post marketing commitment for CHANTIX/CHAMPIX in the U.S. and EU for adolescents 12-16 years and 12-17 years of age, respectively.

March 23, 2018
·
7 min read